Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
Launched by YALE UNIVERSITY · Feb 28, 2022
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving access to Medication Assisted Treatment (MAT) for people in Black and Latinx communities who are struggling with substance use, particularly alcohol and opioids. The study aims to find effective ways to help individuals engage with treatment options that can support their recovery and improve their mental health.
To be eligible to participate, individuals must identify as Black or Latinx, have been using alcohol or opioids within the last 30 days, and be interested in reducing their substance use. Participants will be involved in developing and testing new methods of treatment in their communities. This is an important chance for those who want to make a change in their lives and receive support tailored to their cultural needs. If you or someone you know fits these criteria and is interested, this study may provide valuable resources for recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants must meet criteria for a DSM-5 Alcohol Use Disorder and/or Opioid Use Disorder and are currently using alcohol and/or other opioids within the last 28 days.
- • Are interested in reducing substance use.
- • Self-identify as living in a geographical area with high overdose case rates
- Exclusion Criteria:
- • - Participants who do not sign informed consent
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bridgeport, Connecticut, United States
Bridgeport, Connecticut, United States
Hartford, Connecticut, United States
Hartford, Connecticut, United States
New Haven, Connecticut, United States
New Haven, Connecticut, United States
New Haven, Connecticut, United States
New Britain, Connecticut, United States
Patients applied
Trial Officials
Chyrell Bellamy, Ph.D.
Principal Investigator
Yale University
Ayana Jordan, PhD.
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials